← 返回

泛癌分析揭示,神经营养因子信号与抗肿瘤免疫、临床结局以及对癌症靶向治疗和免疫治疗的应答呈正相关

英文原题:Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer.

查看英文原题

Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer.

PubMed 2021/07/19(内容时间) Life Sci Q1 · IF 6.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究思路按摘要原文分段

癌细胞与神经之间的交互作用在肿瘤生物学中发挥重要作用。然而,神经营养因子信号(NS)与抗肿瘤免疫及癌症免疫治疗反应之间的相关性仍未被探索。

我们分析了33种TCGA癌症类型中NS与抗肿瘤免疫特征、肿瘤免疫相关分子和基因组特征以及临床特征的关联。我们还探讨了四个癌症队列中NS与免疫检查点抑制剂(ICIs)应答之间的关联。

NS评分与抗肿瘤免疫特征的富集评分呈显著正相关,包括在大多数癌症类型中CD8+ T细胞、干扰素反应、NK 细胞、Toll样受体和NOD样受体信号通路。NS评分与多种癌症中的DNA损伤修复通路评分、肿瘤突变负荷、拷贝数改变、肿瘤内异质性和肿瘤干性呈负相关。相反,在33种癌症类型中的32种,NS评分与凋亡通路评分呈显著正相关。在多种癌症中,早期与晚期相比以及原发性与转移性肿瘤相比,NS评分显著较低。较高的NS评分与泛癌和八种个体癌症类型中更好的生存相关。此外,在四个癌症队列中,高NS评分肿瘤对ICIs的缓解率高于低NS评分肿瘤。NS升高与多种抗肿瘤靶向药物的药物敏感性增加相关。意义:NS是癌症中抗肿瘤免疫反应、预后以及对靶向和免疫治疗药物反应的正向生物标志物。

展开英文摘要原文

AIMS: The crosstalk between cancer cells and nerves plays an important role in tumor biology. However, the correlation between the neurotrophin signaling (NS) and anti-tumor immunity and immunotherapy response in cancer remains unexplored. MATERIALS AND METHODS: We analyzed associations of NS with anti-tumor immune signatures, tumor immunity-related molecular and genomic features, and clinical features in 33 TCGA cancer types. We also explored the association between NS and the response to immune checkpoint inhibitors (ICIs) in four cancer cohorts. KEY FINDINGS: NS scores had significant positive correlations with the enrichment scores of anti-tumor immune signatures, including CD8+ T cells, interferon response, natural killer cells, Toll-like receptor and NOD-like receptor signaling pathways in most cancer types. NS scores were inversely correlated with the scores of DNA damage repair pathways, tumor mutation burden, copy number alterations, intra-tumor heterogeneity, and tumor stemness in diverse cancers. In contrast, NS scores were significantly and positively correlated with the apoptosis pathway's scores in 32 of the 33 cancer types. NS scores were significantly lower in early-stage versus late-stage and in primary versus metastatic tumors in diverse cancers. Higher NS scores were correlated with better survival in pan-cancer and in eight individual cancer types. Moreover, the response rate to ICIs was higher in higher-NS-score than in lower-NS-score tumors in four cancer cohorts. Elevated NS was correlated with increased drug sensitivity for numerous anti-tumor targeted drugs. SIGNIFICANCE: NS is a positive biomarker for anti-tumor immune response, prognosis, and the response to targeted and immunotherapeutic drugs in cancer.

论文信息

作者
Feng Q、Song D、Wang X
第一作者单位
Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, China.China
通讯作者单位
Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, China. Electronic address: xiaosheng.wang@cpu.edu.cn.China
期刊
Life sciences2021 Oct 1
原文标识
PubMed 34293398 · DOI 10.1016/j.lfs.2021.119848